Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12.
Publication
, Journal Article
Sha, BE; Onorato, M; Bartlett, JA; Bosch, RJ; Aga, E; Nokta, M; Adams, EM; Li, X-D; Eldridge, J; Pollard, RB
Published in: AIDS
May 21, 2004
We examined the safety and immunogenicity of a human leukocyte antigen-based HIV envelope polyvalent synthetic peptide vaccine, C4-V3, alone and in combination with subcutaneous IL-12 in nine HIV-infected patients. Lymphocyte proliferative responses increased threefold or more to all four peptides at two consecutive post-immunization timepoints for four individuals. Three responders had received IL-12, suggesting a possible adjuvant effect of Il-12. Transient mild injection site reactions (7.9) and systemic symptoms (3/9) occurred.
Duke Scholars
Published In
AIDS
DOI
ISSN
0269-9370
Publication Date
May 21, 2004
Volume
18
Issue
8
Start / End Page
1203 / 1206
Location
England
Related Subject Headings
- Virology
- Vaccines, Synthetic
- Male
- Interleukin-12
- Injections, Intradermal
- Humans
- HLA Antigens
- HIV Infections
- Female
- Drug Therapy, Combination
Citation
APA
Chicago
ICMJE
MLA
NLM
Sha, B. E., Onorato, M., Bartlett, J. A., Bosch, R. J., Aga, E., Nokta, M., … Pollard, R. B. (2004). Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. AIDS, 18(8), 1203–1206. https://doi.org/10.1097/00002030-200405210-00015
Sha, Beverly E., Michelle Onorato, John A. Bartlett, Ronald J. Bosch, Evgenia Aga, Mostafa Nokta, Elizabeth M. Adams, Xiao-Dong Li, John Eldridge, and Richard B. Pollard. “Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12.” AIDS 18, no. 8 (May 21, 2004): 1203–6. https://doi.org/10.1097/00002030-200405210-00015.
Sha BE, Onorato M, Bartlett JA, Bosch RJ, Aga E, Nokta M, et al. Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. AIDS. 2004 May 21;18(8):1203–6.
Sha, Beverly E., et al. “Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12.” AIDS, vol. 18, no. 8, May 2004, pp. 1203–06. Pubmed, doi:10.1097/00002030-200405210-00015.
Sha BE, Onorato M, Bartlett JA, Bosch RJ, Aga E, Nokta M, Adams EM, Li X-D, Eldridge J, Pollard RB. Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. AIDS. 2004 May 21;18(8):1203–1206.
Published In
AIDS
DOI
ISSN
0269-9370
Publication Date
May 21, 2004
Volume
18
Issue
8
Start / End Page
1203 / 1206
Location
England
Related Subject Headings
- Virology
- Vaccines, Synthetic
- Male
- Interleukin-12
- Injections, Intradermal
- Humans
- HLA Antigens
- HIV Infections
- Female
- Drug Therapy, Combination